{"id":"H001","assumption":"Anti-Jo-1 myositis therapeutic development assumes that broad immunosuppression is the optimal approach, focusing on reducing overall immune activity rather than targeting specific molecular interactions","hypothesis":"Structure-guided rational design of therapeutics targeting specific antibody-antigen binding interfaces will provide more effective and targeted interventions than broad immunosuppression","impact":"Challenges the entire therapeutic development framework in autoimmune myositis, potentially unlocking precision medicine approaches","timestamp":"2025-08-22T12:28:00.000Z","status":"proposed"}
{"id":"H002","assumption":"Anti-Jo-1 antibodies are primarily viewed as disease biomarkers for monitoring activity, with limited investigation into how their specific binding mechanisms contribute to pathogenesis","hypothesis":"The structural details of anti-Jo-1 antibody binding to histidyl-tRNA synthetase reveal critical functional epitopes that directly drive pathogenic mechanisms, making these interactions therapeutic targets rather than just diagnostic markers","impact":"Reframes antibodies from passive markers to active participants in disease mechanisms, opening new therapeutic avenues","timestamp":"2025-08-22T12:28:00.000Z","status":"proposed"}
{"id":"H003","assumption":"The myositis field assumes that structural biology approaches (cryoEM/X-ray crystallography) are not necessary or practical for understanding autoimmune mechanisms, relying instead on functional and clinical studies","hypothesis":"High-resolution structural analysis of anti-Jo-1 antibody-HisRS complexes will reveal previously unknown binding mechanisms and allosteric effects that explain disease pathogenesis and guide therapeutic design","impact":"Introduces a new methodological paradigm to autoimmune disease research, potentially applicable across multiple conditions","timestamp":"2025-08-22T12:28:00.000Z","status":"proposed"}
{"id":"H004","assumption":"Current immune retolerization strategies for autoimmune diseases focus on general immune modulation without considering specific molecular recognition patterns","hypothesis":"Structural understanding of anti-Jo-1 antibody-HisRS binding will enable design of specific retolerization therapies that target the molecular basis of self-recognition failure","impact":"Could transform autoimmune disease treatment from immunosuppression to immune system re-education","timestamp":"2025-08-22T12:28:00.000Z","status":"proposed"}
{"id":"H005","assumption":"Epitope mapping in autoimmune diseases is primarily conducted through functional assays rather than high-resolution structural determination","hypothesis":"Crystallographic epitope mapping of anti-Jo-1 antibodies will identify previously unknown conformational epitopes and binding mechanisms not detectable by traditional functional approaches","impact":"Establishes structural biology as essential methodology for autoimmune disease research and therapeutic development","timestamp":"2025-08-22T12:28:00.000Z","status":"proposed"}